Connect with us

Technology

SITC Announces Keynote Speaker Dr. Ignacio Melero at the Immuno-oncology Drug Development Summit

Published

on

The Society for Immunotherapy of Cancer (SITC) is excited to announce that Ignacio Melero, MD, PhD from the Clinica Universidad de Navarra Medical School and Cima will present his keynote on Cancer Immunotherapy: Tomorrow’s Treatment Combinations Today at its Immuno-oncology Drug Development Summit.

MILWAUKEE, June 11, 2024 /PRNewswire-PRWeb/ — The Society for Immunotherapy of Cancer (SITC) is excited to announce that Ignacio Melero, MD, PhD from the Clinica Universidad de Navarra Medical School and Cima will present his keynote on Cancer Immunotherapy: Tomorrow’s Treatment Combinations Today at its Immuno-oncology Drug Development Summit.

“SITC is excited to gather leaders from diverse sectors of the drug development ecosystem, including biotech, pharma, academia, government, and finance, to discuss bringing new cancer therapeutics to patients in a more rapid fashion.” – Leisha A. Emens, MD, PhD, President of SITC

The SITC Immuno-oncology Drug Development Summit will take place on Sept. 30–Oct. 1, 2024, at the Revere Hotel Boston Common in Boston, MA. The Summit will educate and engage the entire immuno-oncology (IO) community on the next wave of IO therapeutics and ensure that active, innovative, new therapies are rapidly and appropriately moved into the clinical testing. This program will be a key forum for continuing exploration and discussion of best practices for modern IO drug development, including study design, regulatory pathways and emerging technologies.

“SITC is excited to gather leaders from diverse sectors of the drug development ecosystem, including biotech, pharma, academia, government, and finance, to discuss bringing new cancer therapeutics to patients in a more rapid fashion,” remarked Leisha A. Emens, MD, PhD, President of SITC. “This summit closely aligns to SITC’s goal of 100 approvals of new and novel IO agents in the next decade.”

Day one of the IO Drug Development Summit begins with a primer on the drug development process, including sessions about preclinical models and IO clinical protocol development as well as clinical trial design, terminology and endpoints. FDA representatives will also address recent and ongoing FDA initiatives, such as Project Optimus and Project FrontRunner.

Day two will focus on strategies and hot topics in drug development. Provocative questions concerning the future of IO will be explored during our fireside chat with Priti Hegde, PhD, from Kite Pharma and Jedd D. Wolchok, MD, PhD, from Weill Cornell Medicine. Alexandra Snyder, MD, of Generate Biomedicines will moderate the fireside chat. Additional day two content includes investor perspectives on chimeric antigen receptors, AI and immune cell engagers.

“There has been tremendous success in the clinical advancement of cancer immunotherapy in the past decade, with 29 new IO drugs achieving FDA approval in this time,” remarked Jon M. Wigginton, MD, Co-Organizer of the SITC Immuno-oncology Drug Development Summit. “This has required active collaboration between patients, academia, the pharma/biotech ecosystem, regulatory agencies and investors to realize this progress. This summit is intended to bring key stakeholders in the field together to educate and reflect on key lessons learned, and to actively discuss the opportunities and challenges for the field going forward.”

Registration for the SITC Immuno-oncology Drug Development Summit is now open. View the entire schedule of expert speakers and session topics at the SITC IO Drug Development web page. Early registration closes Aug. 31. SITC Members receive a discount on registration rates.

About SITC
Established in 1984, the Society for Immunotherapy of Cancer (SITC) is a nonprofit organization of medical professionals dedicated to improving cancer patient outcomes by advancing the development, science and application of cancer immunotherapy and tumor immunology. SITC is comprised of influential basic and translational scientists, practitioners, health care professionals, government leaders and industry professionals around the globe. Through educational initiatives that foster scientific exchange and collaboration among leaders in the field, SITC aims to one day make the word “cure” a reality for cancer patients everywhere. Learn more about SITC, our educational offerings and other resources at sitcancer.org and follow us on X, LinkedIn, and YouTube.

Media Contact

Thomas Martin, Society for Immunotherapy of Cancer, 414-271-2456, tmartin@sitcancer.org, www.sitcancer.org

Twitter LinkedIn

View original content to download multimedia:https://www.prweb.com/releases/sitc-announces-keynote-speaker-dr-ignacio-melero-at-the-immuno-oncology-drug-development-summit-302169209.html

SOURCE Society for Immunotherapy of Cancer

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

JAMS Launches AI for Enterprise Job Scheduling: JAX and JAMS MCP, on the Model You Choose

Published

on

By

A new AI agent and an open-standard connector let IT teams query, diagnose, and manage automation in plain language, on the model they choose, with operational data staying inside their own network

LONDON, July 24, 2026 /PRNewswire/ — JAMS Software, an orchestration solution for scheduled and event-driven automation, today announced the general availability of two AI capabilities for enterprise job scheduling: JAX, an AI agent built into the JAMS Web Client, and JAMS MCP, a connector built on the open Model Context Protocol standard that brings JAMS into external AI coding tools. Both capabilities ship at no additional cost as part of JAMS Web.

Automation environments grow faster than the teams that run them. Jobs multiply across SQL Server, Azure Data Factory, Airflow, SAP, JDE, and Banner, and when one fails, finding the root cause often means searching several consoles at once, frequently outside business hours. At the same time, IT leaders carry pressure to adopt AI while staying accountable for where operational data goes. JAX and JAMS MCP close both gaps together.

Full details on how JAX and JAMS MCP work, including the control model behind every action, are available at jamsscheduler.com/product/ai.

JAX is an AI agent that runs inside the JAMS Web Client. It finds jobs, troubleshoots failures, and answers how-to questions in plain language, with each response grounded in the JAMS user guide and checked against a built-in glossary. JAX acts only when a user asks it to. Reads flow freely, and every write action pauses for the user’s explicit approval before it runs. JAX does not learn between sessions, and conversations are not retained on the server.

JAMS MCP is a connector, built on the open Model Context Protocol standard, that brings JAMS into the AI tools engineering teams already use, including Cursor, VS Code with Copilot, Claude Code, Claude Desktop, and Codex. Users query jobs, investigate failures, and manage runs in plain language without leaving their tool.

Both capabilities run inside the customer’s own network and act as the signed-in user, with that user’s exact JAMS permissions. There is no elevated AI account: whatever a user cannot do in the JAMS interface, JAX and JAMS MCP cannot do on that user’s behalf. Every JAX and MCP operation is recorded in its own dedicated log, and changes made through the JAMS API land in the JAMS audit trail like any other change. Customers choose their own AI model, whether a commercial provider such as OpenAI or Anthropic or a model running entirely on their own hardware, and JAMS never trains on customer data. In the current release, neither feature edits or deletes a job, folder, schedule, or agent definition. For teams that must keep operational data within a defined boundary, JAX runs on a local model entirely inside the customer’s own network, so nothing leaves at all.

“Adopting AI usually means giving something up, most often visibility into where your data goes,” said Pete Hegland, Chief Executive Officer of JAMS Software. “We built JAX and JAMS MCP so that trade does not have to happen. Every action runs as the signed-in user, every change waits for approval, and the model itself can run entirely inside your own network.”

“IT teams across the United Kingdom and EMEA tell us the same thing: they want the benefit of AI without losing sight of where their data goes,” said Greg McLaughlin, Account Executive for EMEA at JAMS Software. “JAX and JAMS MCP let them keep operational data inside their own network and still get answers in plain language. That combination is what makes this practical for the teams I work with.”

JAX and JAMS MCP are available now to all JAMS Web customers across the United Kingdom and EMEA, with no separate licence, SKU, or additional cost. AI-assisted creation of new jobs and workflows from a plain-language description is on the roadmap for a future release, gated by the same approvals and permissions as every other action.

Learn how JAX and JAMS MCP work at https://jamsscheduler.com/product/ai.

Fast facts

JAX is an AI agent built into the JAMS Web Client for job scheduling and workflow automation.JAMS MCP is a connector built on the open Model Context Protocol standard, for Cursor, VS Code with Copilot, Claude Code, Claude Desktop, and Codex.Both act as the signed-in user, with that user’s exact JAMS permissions, and there is no elevated AI account.Customers choose the AI model, including a local model that runs entirely inside their own network.JAMS never trains on customer data.Both are available now at no additional cost as part of JAMS Web.

About JAMS Software

Founded in 1987, JAMS Software is an orchestration solution that helps IT teams centralize, automate, and manage scheduled and event-driven jobs across complex, hybrid environments. Over 850 customers rely on JAMS to run their automated workloads. JAMS Software, LLC is headquartered at 108 Patriot Drive, Suite A, Middletown, DE 19709.

Media Contact
Bobby Schmidt, Vice President of Marketing
press@jamssoftware.com
800.261.4267

 

 

Logo – https://mma.prnewswire.com/media/3007577/JAMS_logo.jpg
Photo – https://mma.prnewswire.com/media/3007578/jams_jax_ai_agent_job_scheduling_1.jpg
Photo – https://mma.prnewswire.com/media/3007579/jams_jax_mcp_ai_control_model.jpg
Photo – https://mma.prnewswire.com/media/3007580/jams_mcp_ai_connector_claude_cursor.jpg

View original content:https://www.prnewswire.co.uk/news-releases/jams-launches-ai-for-enterprise-job-scheduling-jax-and-jams-mcp-on-the-model-you-choose-302833908.html

Continue Reading

Technology

Video: CNPC offers green chemical answer

Published

on

By

BEIJING, July 24, 2026 /PRNewswire/ — A news report from chinadaily.com.cn:

Located on the edge of the Taklamakan Desert in Northwest China’s Xinjiang Uygur autonomous region, the Tarim 1.2 MTA Phase II Ethylene Project and its supporting green and low-carbon demonstration facility of PetroChina Dushanzi Petrochemical Company, a subsidiary of China National Petroleum Corporation, are offering a new example of China’s low-carbon industrial transformation.

Watch the video to discover how CNPC is exploring a cleaner and more circular future for the industry.

View original content to download multimedia:https://www.prnewswire.com/apac/news-releases/video-cnpc-offers-green-chemical-answer-302834036.html

SOURCE chinadaily.com.cn

Continue Reading

Technology

Shanghai Electric showcases embodied intelligence robot matrix and AI-native smart factory solutions at WAIC 2026

Published

on

By

Featuring humanoid robots with 41 degrees of freedom, pipe‑inspection robots with ±1mm positioning accuracy, and 51 industrial‑grade AI agents

SHANGHAI, July 24, 2026 /PRNewswire/ — Operations in high-end equipment manufacturing often involve confined spaces, complex objects, and fine manipulation tasks that demand sustained and stable precision. At the recent 2026 World Artificial Intelligence Conference and High-Level Meeting on Global AI Governance (WAIC 2026), Shanghai Electric (SEHK: 02727, SSE: 601727) showcased its comprehensive portfolio of embodied intelligence solutions tailored to a range of industrial scenarios.

Themed “AI for All: Smart Squad, Shining Without Limits,” Shanghai Electric highlighted its capabilities across embodied AI robots, robot core components, and AI-native smart factory solutions, demonstrating end-to-end capabilities spanning complete robot systems, critical parts, industrial software, and smart factory architecture.

“The true value of embodied intelligence lies in understanding real industrial tasks: combining the strength, precision, and stability of machines with human experience and judgment to drive a genuine paradigm of ‘machine-assisted, human-machine collaboration,'” said Wang Chunlei, deputy general manager of the Robotics Business Unit at Shanghai Electric Automation Group.

Shanghai Electric’s robotics portfolio covers five key industrial scenarios: connector insertion, electrical operations, flexible sorting, intelligent assembly, and pipe processing. Highlights include:

“SUYUAN” bipedal humanoid robot: With 41 degrees of freedom for enhanced mobility, it is equipped with a multimodal visual sensing system on the head and torso, along with a dual-battery hot-swap system. It is well-suited for inspection, material handling, and assembly tasks.”TUOYUAN” industrial wheeled humanoid robot: Powered by an embodied intelligence foundation model and force-position hybrid control, it is capable of multi-spec connector insertion, material sorting, and loading/unloading of automotive sheet metal parts.”Mermaid” bionic wheeled humanoid robot: Capable of autonomously identifying buttons, knobs, and air switches, it generates real-time operation paths.Autonomous pipe inner-wall chamfering robot: Designed for confined spaces, it can position and process thousands of hole edges with accuracy within 1 millimeter while transmitting data in real time.

Shanghai Electric also showcased its portfolio of core components ranging from power-output to end effectors. Among them, the planetary roller screw offers more than three times the load capacity of traditional ball screws, while the DexHand dexterous hand is designed to meet diverse gripping and manipulation requirements.

Shanghai Electric launched 51 AI models and agents under its “StarCloud Intelligent Manufacturing” series across three domains: R&D and design, production and manufacturing, and operations and maintenance—covering critical equipment processes such as process optimization and wind power facility maintenance.

These industrial agents are embedded in robotic decision-making systems and the operational logic of AI-native smart factories, transforming industrial expertise into digitized, reusable capabilities. They support production-line scheduling, quality inspection, and predictive maintenance, driving the evolution of manufacturing systems from experience-driven to data-driven operations.

Shanghai Electric also released the “AI-Native Smart Factory Technology White Paper,” proposing an active evolution architecture that enables real‑time, closed‑loop optimization of production data, giving the factory self‑perception, self‑decision, and self‑execution capabilities. Built on First Principles, the AI‑native smart factory vertically integrates process flows, industrial software, agents, and smart equipment to dismantle traditional hierarchies while horizontally bridging data silos. The architecture features three core layers: the AI factory brain as the “control center,” industrial agents and embodied robots as the “execution network,” and the physical twin as the “digital mirror.”

Leveraging its deep industrial expertise and comprehensive solution capabilities, Shanghai Electric will continue to drive the implementation of AI in industrial settings, tackle technical challenges facing embodied intelligence in complex scenarios, accelerate the large‑scale deployment of AI‑native smart factories, and deliver replicable solutions across diverse manufacturing environments.

SOURCE Shanghai Electric

Continue Reading

Trending